Search research articles
Contact Us
Filters
Showing results (901-910 of 1,482) with videos related to
Page
of 149
Sort By:
Blood Advances
|
December 4, 2024
Impact of measurable residual disease clearance kinetics in patients with AML undergoing intensive chemotherapy
Wei-Ying Jen, Koji Sasaki, Farhad Ravandi, et al.
The Lancet. Microbe
|
November 15, 2024
Performance of stool-based molecular tests and processing methods for paediatric tuberculosis diagnosis: a systematic review and meta-analysis
Lucía Carratalà-Castro, Shilzia Munguambe, Belén Saavedra-Cervera, et al.
Leukemia
|
August 1, 2020
Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results
Michael Heuser, Neil Palmisiano, Ioannis Mantzaris, et al.
Haematologica
|
October 2, 2025
Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor
Nicholas J Short, Sanam Loghavi, Musa Yilmaz, et al.
Genes, Chromosomes & Cancer
|
May 24, 2023
The landscape of BRCA1 and BRCA2 large rearrangements in an international cohort of over 20 000 ovarian tumors identified using next-generation sequencing
Melanie A Jones, Kirsten M Timms, Shanell Hatcher, et al.
Nature Biomedical Engineering
|
June 27, 2025
Self-powered rapid antigen-specific T-cell response assay for Mycobacterium tuberculosis infections
Bo Ning, Sutapa Chandra, Yongchun Pan, et al.
Blood Advances
|
July 24, 2025
Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML
Pau Montesinos, Dylan M Marchione, Christian Récher, et al.
American Journal of Hematology
|
January 12, 2017
Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents
Elias Jabbour, Paolo Strati, Monica Cabrero, et al.
Transfusion
|
April 20, 2022
The Recipient Epidemiology and Donor Evaluation Study-IV-Pediatric (REDS-IV-P): A research program striving to improve blood donor safety and optimize transfusion outcomes across the lifespan
Cassandra D Josephson, Simone Glynn, Sunitha Mathew, et al.
Cancers
|
November 27, 2024
Cladribine-Based Therapy for Acute Myeloid Leukemia in Child, Adolescent, and Early Young Adult Patients: The MD Anderson Cancer Center Experience
David McCall, Shaikha Alqahtani, Moriah Budak, et al.
Page
of 149
Search research articles
Search
Showing results (901-910 of 1,482) with videos related to
Sort By:
Page
of 149
Blood Advances
|
December 4, 2024
Impact of measurable residual disease clearance kinetics in patients with AML undergoing intensive chemotherapy
Wei-Ying Jen, Koji Sasaki, Farhad Ravandi, et al.
The Lancet. Microbe
|
November 15, 2024
Performance of stool-based molecular tests and processing methods for paediatric tuberculosis diagnosis: a systematic review and meta-analysis
Lucía Carratalà-Castro, Shilzia Munguambe, Belén Saavedra-Cervera, et al.
Leukemia
|
August 1, 2020
Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results
Michael Heuser, Neil Palmisiano, Ioannis Mantzaris, et al.
Haematologica
|
October 2, 2025
Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor
Nicholas J Short, Sanam Loghavi, Musa Yilmaz, et al.
Genes, Chromosomes & Cancer
|
May 24, 2023
The landscape of BRCA1 and BRCA2 large rearrangements in an international cohort of over 20 000 ovarian tumors identified using next-generation sequencing
Melanie A Jones, Kirsten M Timms, Shanell Hatcher, et al.
Nature Biomedical Engineering
|
June 27, 2025
Self-powered rapid antigen-specific T-cell response assay for Mycobacterium tuberculosis infections
Bo Ning, Sutapa Chandra, Yongchun Pan, et al.
Blood Advances
|
July 24, 2025
Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML
Pau Montesinos, Dylan M Marchione, Christian Récher, et al.
American Journal of Hematology
|
January 12, 2017
Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents
Elias Jabbour, Paolo Strati, Monica Cabrero, et al.
Transfusion
|
April 20, 2022
The Recipient Epidemiology and Donor Evaluation Study-IV-Pediatric (REDS-IV-P): A research program striving to improve blood donor safety and optimize transfusion outcomes across the lifespan
Cassandra D Josephson, Simone Glynn, Sunitha Mathew, et al.
Cancers
|
November 27, 2024
Cladribine-Based Therapy for Acute Myeloid Leukemia in Child, Adolescent, and Early Young Adult Patients: The MD Anderson Cancer Center Experience
David McCall, Shaikha Alqahtani, Moriah Budak, et al.
Page
of 149